Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
SPCX$132.15-3.77(-2.77%)Stack Capital Group Inc. Reports Q3-2026 Financial Results7:45:00 AM ETCOP$138.49+1.55(+1.13%)BUZZ-ConocoPhillips rises on Q3 profit beat7:40:48 AM ETTGT$164.75+1.70(+1.04%)Target Looks More Attractive Than You'd Think7:31:07 AM ETCOP$138.49+1.55(+1.13%)UPDATE 2-ConocoPhillips beats estimates on higher oil prices, raises dividend7:30:23 AM ETCOP$138.49+1.55(+1.13%)ConocoPhillips Q3 profit beats on higher prices, hikes dividend7:26:13 AM ETMETA$637.14+7.14(+1.13%)UPDATE 2-Meta sells first bonds in euros, raises €9 billion7:25:25 AM ETDTE$137.45-0.06(-0.04%)UPDATE 1-DTE Energy to sell its non-utility business for about $3 billion7:23:30 AM ETAAPL$352.33+2.82(+0.81%)Jim Cramer's Surprise Midterm Winner: Apple, Because Fewer Data Centers Could Mean Cheaper Memory7:19:09 AM ETTSLA$377.00-8.19(-2.13%)Ferrari vs. Tesla: Can the Luce Outsell the Roadster?7:18:00 AM ETMU$757.49-37.97(-4.77%)Could Buying Micron Stock Today Help Set You Up for Life?7:17:00 AM ETMSFT$556.10+0.30(+0.05%)Microsoft Is Executing an Irreproducible Balance-Sheet-Backed Infrastructure Pre-Sale at Scale7:15:58 AM ETAAPL$352.33+2.82(+0.81%)Apple Vs. Tesla: Low CapEx Only Matters if Non-Cyclical Cash Flows Come With It7:15:57 AM ETIREN$20.88-0.82(-3.78%)IREN is Only Fit for a Specific Investor Currently7:15:22 AM ETCOP$138.49+1.55(+1.13%)BRIEF-Conocophillips Q3 Adjusted EPS USD 3.27 Vs. IBES Estimate USD 2.977:13:20 AM ETMU$757.49-37.97(-4.77%)Micron Just Closed Below $800 for the First Time Since July7:12:48 AM ETAAPL$352.33+2.82(+0.81%)Amazon, Apple, FTAI Aviation And A Basic Material Stock: CNBC's ‘Final Trades'7:12:08 AM ETCOP$138.49+1.55(+1.13%)ConocoPhillips beats profit estimates, boosts quarterly dividend7:11:13 AM ETCRWD$233.22-7.78(-3.23%)Too Late to Buy CrowdStrike Stock? Here's the 1 Thing to Watch.7:10:00 AM ETGOOG$289.72+2.42(+0.84%)These 6 Stocks Make Up a Big Share of the S&P 5007:09:00 AM ETCOP$138.49+1.55(+1.13%)UPDATE 1-ConocoPhillips beats profit estimates, boosts quarterly dividend7:07:07 AM ETLLY$1,433.00+14.86(+1.05%)Iconic California Brand, French Florist, Celebrates Grand Opening of First Indiana Location7:07:00 AM ETCVS$80.93+0.94(+1.18%)ProjectLeo, the First Private AI Health Platform to Declare Independence From Big Tech7:04:00 AM ETCOP$138.49+1.55(+1.13%)ConocoPhillips beats quarterly profit estimates7:01:40 AM ETCOP$138.49+1.55(+1.13%)ConocoPhillips announces third-quarter 2026 results and increases quarterly ordinary dividend by 11%7:00:05 AM ET

AMLX · NASDAQ

Amylyx Pharmaceuticals, Inc.

$29.88 +0.49 (+1.67%)

Company overview

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$3.8B
Employees
123
Headquarters
Cambridge, MA
Website
amylyx.com
CEO
Joshua Cohen
Listed
January 7, 2022
P/E
-20.19
Dividend yield
5.64%

Company financials

Revenue
$0.00
Gross profit
-$20.2M
Operating income
-$159M
EBITDA
-$150M
Net income
-$150M
EPS
-$1.48
Total assets
$294M
Total debt
$5.6M
Earnings yield
-4.95%

Price chart

11.2919.0426.7934.5442.29
AMLX 1D NASDAQ O30.65H30.68L27.90C29.39+0.19 (+0.65%)Vol1.35M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
AMLXAmylyx Pharmaceuticals, Inc. Stock news Amylyx Pharma Q3 net loss bigger than expected Reuters
AMLXAmylyx Pharmaceuticals, Inc. Stock news BRIEF-Amylyx Pharmaceuticals Q3 EPS USD -0.38 Vs. IBES Estimate USD -0.38 Reuters
AMLXAmylyx Pharmaceuticals, Inc. Press release Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results Business Wire
AMLXAmylyx Pharmaceuticals, Inc. Press release Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts Business Wire
AMLXAmylyx Pharmaceuticals, Inc. Press release Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences Business Wire
AMLXAmylyx Pharmaceuticals, Inc. Press release Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 Business Wire
AMLXAmylyx Pharmaceuticals, Inc. Stock news 11 Stocks Most Likely to See a Short Squeeze Rally Schaeffers Research
AMLXAmylyx Pharmaceuticals, Inc. Press release Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting Business Wire
AMLXAmylyx Pharmaceuticals, Inc. Stock news Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment MarketBeat
AMLXAmylyx Pharmaceuticals, Inc. Stock news 10 Stocks With Massive Short Squeeze Potential Schaeffers Research
AMLXAmylyx Pharmaceuticals, Inc. Press release Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum Business Wire
AMLXAmylyx Pharmaceuticals, Inc. Stock news Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
AMLXAmylyx Pharmaceuticals, Inc. Press release Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors Business Wire
AMLXAmylyx Pharmaceuticals, Inc. Press release Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference Business Wire
AMLXAmylyx Pharmaceuticals, Inc. Stock news Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? The Motley Fool
AMLXAmylyx Pharmaceuticals, Inc. Stock news Should Eli Lilly Investors Be Worried About a Threat From Amylyx? The Motley Fool
AMLXAmylyx Pharmaceuticals, Inc. Stock news BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX Defense World
AMLXAmylyx Pharmaceuticals, Inc. Stock news BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX Defense World
AMLXAmylyx Pharmaceuticals, Inc. Stock news Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week The Motley Fool
AMLXAmylyx Pharmaceuticals, Inc. Stock news Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock GuruFocus
See more
FAQ

Questions about Amylyx Pharmaceuticals, Inc.

What does Amylyx Pharmaceuticals, Inc. do?
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
What is AMLX's market cap?
Amylyx Pharmaceuticals, Inc. (AMLX) is a listed stock with a live quote. The latest market cap on this page is $3.8B.
Where is Amylyx Pharmaceuticals, Inc. headquartered?
Amylyx Pharmaceuticals, Inc. is headquartered in Cambridge, MA.
How do I get AMLX news from the API?
Call GET /v1/news?tickers=AMLX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does AMLX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for AMLX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the AMLX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs